Markh Drazner News Today

/PRNewswire/ -- Efforts by the American College of Cardiology, the American Heart Association, the Heart Failure Society of America, the Heart Rhythm Society...

Tough questions need asking. Should xenotransplant research have its own rules? Should society be wary of the unique risks? Should patients bear extra responsibilities and give up some rights?

Adding the IV drug to loop diuretics in the ADVOR trial improved decongestion success in volume-overloaded patients with acute decompensated heart failure, researchers reported.

Despite earlier successes, the experimental agent was no better than placebo in improving exercise capacity in the phase 3 METEORIC-HF trial.

With stocks not expected to stabilize until late this year or early next, hospitals should be planning ahead, one expert says.

Why have SGLT2-inhibitor clinical benefits in HFrEF trials been evident so soon after the drugs are started? Recent studies shed light on one potential mechanism among what are probably many.

Annual influenza vaccines significantly cut death during serial flu seasons in patients with heart failure in the prospective, placebo-controlled IVVE trial.